

APCCC Detailed Programme 2022 (subject to changes)

The following controversial areas related to the management of men with APC have been selected for discussion in 2022:

For all talks

- What is new (last 2 years)
 - What is evidence, where are the grey zones
 - Which trials address the open issues
1. **Locally advanced and prostate cancer**
 - a. **Imaging**
 - b. **Biomarkers/genomic classifiers**
 - a. **Management (including cN1 and pN1)**
 2. **Biochemical recurrence/PSA persistence after local therapy**
 - a. **Imaging**
 - b. **Genomic classifiers**
 - c. **Treatment options**
 3. **Management of metastatic hormone-sensitive prostate cancer (HSPC)**
 - a. **Management of primary tumour in the metastatic setting**
 - b. **Systemic therapies**
 - c. **Oligometastatic**
 - d. **Health economic considerations (including circulating tumour markers)**
 4. **Management of metastatic CRPC**
 - a. **Sequencing of treatment options (talk on how to keep better targeting the AR axis beyond abi/enza and whether stratifying patients based on the AR biology (amplification vs mutations vs neutral vs variants) may help us or not)**
 - b. **Oligoprogressive**
 - c. **Lutetium PSMA (including not only PSMA-Lu but also other means of PSMA targeting such as bites, actinium, etc)**
 - d. **Cross-resistance**
 - e. **Novel Targets (e.g. AKT)**
 5. **Staging and Treatment monitoring**
 - a. **Imaging including PSMA**
 - b. **Toxicity**
 6. **Somatic genomic profiling**
 - a. **DNA repair aberrations**
 - b. **How to read a report (e.g. Foundation medicine)**
 - c. **Other actionable alterations**
 7. **Germline**
 8. **Importance of lifestyle/comorbidities**
 - a. **Nutrition and Supplemental medicines (vitamins, folate), dietary manipulations**
 - b. **Exercise**
 - c. **Bone health**
 - d. **Immune-suppression**
 9. **Socio-economic status and impact on cancer care**
 - a. **including lessons learnt from the covid 19 pandemic**
 - b. **Prioritization diagnostics (biomarkers), imaging, and therapeutics, regardless of 'developed or developing' healthcare ecosystem, 'optimizing telemedicine, risk-benefit assessments, delayed diagnosis and effects. How pandemics alter prostate cancer care (trials need to be done telemedicine vs standard monitoring)**

Thursday 28th April 2022			
Time	Welcome Address		
09:00	Why an Advanced Prostate Cancer Consensus Conference?	Silke Gillessen Aurelius Omlin	10 Minutes
09:10	What is important from a patient's perspective?		
9:20 - 10:45 Session 1	High-risk and locally advanced prostate cancer	Chairs:	Duration
	Impact of novel imaging in staging		
	Impact of histology variants (ductal/intraductal/cribriform) on treatment recommendation		
	Management of cN1 prostate cancer (including systemic therapy)		
	Management of pN1 disease (including systemic therapy)		
	Who needs early salvage RT and who needs adjuvant RT in 2022?		
Discussion (25 min)			
COFFEE BREAK			
11:15 – 12:45 Session 2	Biochemical recurrence	Chairs:	Duration
	Who needs systemic treatment with salvage RT?		
	Biochemical recurrence after definitive radiotherapy of the prostate – what are the local treatment options?		
	Debate		
	<ul style="list-style-type: none"> Imaging directed treatment for BCR PSA directed treatment for BCR 		
	How can treatment be individualised by using genomic classifiers?		
Discussion (30min)			
12:45 – 13:45 LUNCH			
13:45 – 15:45 Session 3	Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs:	Duration
	mHSPC: Do we need more granularity?		
	<ul style="list-style-type: none"> Systemic treatment options for the different subgroups Can biology help for treatment decisions? 		
	Treatment of the primary tumour in mHSPC		
	Treatment of vulnerable/frail patients with mHSPC		
Discussion (13 min)			
	Optimal treatment for mHSPC from a health economics standpoint		

	Uptake of new treatment options for mHSPC in real live – education and access and use		
	Treatment de-escalation strategies in mHSPC		
	Treatment intensification strategies in mHSPC		
Discussion (15min)			
COFFEE BREAK			
16:15 – 17:15 Session 4	Importance of lifestyle and prevention of complications	Chairs:	Duration
	How to take care of the bones?		
	How to take care of the heart?		
	How to take care of muscle strength?		
	How to take care of brain and mood?		
Discussion (15min)			

Friday 29th April 2022			
Extra session 08:00 – 08:30	Movember Session	Chair:	Duration
Update on IRONMAN Project			
Discussion (10min)			
08:30 – 09:30 Session 5	Management of non-metastatic CRPC	Chairs:	Duration
Non-metastatic CRPC:			
<ul style="list-style-type: none"> • Overview of treatment options (including treatment monitoring and side effect management, bone health etc) 			
<ul style="list-style-type: none"> • Advantages of using novel imaging in nmCRPC 			
<ul style="list-style-type: none"> • Disadvantages of using novel imaging in nmCRPC 			
<ul style="list-style-type: none"> • How can treatment be individualised by using genomic classifiers? 			
Discussion (18min)			
COFFEE BREAK			
10:00 - 11:15 Session 6 part 1	Management of metastatic CRPC	Chairs:	Duration
Tumour genomic profiling: What is relevant?			
<ul style="list-style-type: none"> • In tissue 			
<ul style="list-style-type: none"> • Liquid biopsy 			
Potential pitfalls in PARP inhibitor related diagnostics			
Update on targeted therapies in mCRPC (PARP, checkpoint inhibitors, AKT...)			
Chemotherapy options and when to use them? (docetaxel, cabazitaxel, including docetaxel re-challenge after use in HSPC, platinum, other options)			
Discussion (15min)			
COFFEE BREAK			

11:45 – 13:00 Session 6 part 2	Management of metastatic CRPC	Chairs:	Duration
Is there still a role for radium-223?			
Optimal treatment sequencing in mCRPC			
Aggressive variant prostate cancer: Definition, diagnosis, treatment			
Risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often)			
Discussion (20min)			
13:00 – 14:00 LUNCH			
14:00 – 15:15 Session 7	PET imaging and Lutetium-PSMA for therapy	Chairs:	Duration
What is the optimal (current) tracer for PET-based imaging and what is on the horizon?			
How to select patients for treatment with Lutetium-PSMA			
Lutetium-PSMA therapy			
How to follow-up patients who had PSMA PET as baseline imaging? (high-risk, BCR, HSPC, CRPC...)			
Discussion (18min)			
COFFEE BREAK			
15:45 – 16:45 Session 8	Oligometastatic and oligoprogressive prostate cancer	Chairs:	Duration
What are the different subgroups and what is the evidence for MDT in each of them?			
What is the evidence of systemic therapies (alone or in combination with MDT) in each of the different subgroups?			
Are there predictors for successful treatment of oligometastatic prostate cancer?			
Does oligoprogressive CRPC exist as a distinct clinically meaningful entity and if yes, how to treat it?			
Discussion (15min)			
COFFEE BREAK			
17:15 – 18:15 Session 9	Varia	Chair:	Duration
Which prostate cancer patients need genetic counselling and testing and what to test?			
How to read a genomic testing report (e.g. Foundation medicine, Oncomine etc)			
Real-time data in prostate cancer: the future			
Discussion (15min)			

Saturday 30 th of April 2022		
Time	Special Session	Speakers
08:30 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS Moderation: TBD

COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS Moderation: TBD
Closing Remarks: S.Gillessen and A.Omlin		